Condensed Consolidated Interim Financial Statements
Three and Six Months Ended June 30, 2019 and 2018
(Unaudited)

Condensed Consolidated Interim Statements of Financial Position (In thousands of United States dollars) (Unaudited)

	June 30, 2019		December 31, 2018	
ASSETS			,	
Current assets				
Cash and cash equivalents	\$	11,706	\$	11,920
Trade receivables		13,823		11,292
Amounts due from joint ventures (note 7)		10,602		10,873
Other receivables		819		332
Inventories (note 4)		17,744		22,485
Biological asset (note 5)		5,429		4,230
Prepaid expenses and deposits		1,623		889
Total current assets		61,746		62,021
Non-current assets				
Property, plant and equipment (note 6)		68,665		77,479
Due from joint ventures (note 7)		5,745		-
Right-of-use assets (note 3)		3,988		-
Investment in joint ventures (note 7)		55,197		18,108
Other as sets		1,718		2,207
Total assets	\$	197,059	\$	159,815
LIABILITIES				
Current liabilities				
Line of credit	\$	5,000	\$	2,000
Trade payables		9,389		14,601
Current maturities of long-term debt (note 8)		3,439		3,414
Accrued liabilities		6,730		3,509
Lease liabilities - current (note 3)		913		78
Total current liabilities		25,471		23,602
Non-current liabilities				
Long-term debt (note 8)		30,791		32,445
Deferred tax liability		2,259		1,920
Lease liabilities (note 3)		3,201		102
Other liabilities		1,205		1,050
Total liabilities		62,927		59,119
SHAREHOLDERS' EQUITY				
Share capital		76,435		60,872
Contributed surplus		3,425		2,198
Revaluation surplus (note 6)		3,351		4,321
Accumulated other comprehensive loss		(482)		(562)
Retained earnings		51,403		33,867
Total shareholders' equity		134,132		100,696
Total liabilities and shareholders' equity	\$	197,059	\$	159,815

 $\label{thm:companying} \textit{The accompanying notes are an integral part of these condensed consolidated interim \textit{financial statements}.}$

Village Farms International, Inc. Condensed Consolidated Interim Statements of Changes in Shareholders' Equity (In thousands of United States dollars, except for shares outstanding) (Unaudited)

	Number of							Accı	umulated Other				Total
	Common	Share		Share Contributed		Re	Revaluation Comprehensive		Retained		Shareholders'		
-	Shares		Capital	;	Surplus		Surplus	(L	oss) Income		Earnings		Equity
Balance at January 1, 2018 (restated - note 3)	42,242,612	\$	36,115	\$	1,726	\$	4,321	\$	(391)	\$	39,012	\$	80,783
Shares issued on exercise of stock options Shares issued pursuant to private placement of	342,733		263		-		-		-		-		263
common shares, net of issuance costs	1,886,793		7,755		-		-		-		-		7,755
Share-based compensation (note 16)	-		-		256		-		-		-		256
Cumulative translation adjustment	-		-		-		-		(89)		-		(89)
Net loss	-		-		-		-		-		(3,426)		(3,426)
Balance at June 30, 2018	44,472,138	\$	44,133	\$	1,982	\$	4,321	\$	(480)	\$	35,586	\$	85,542
Balance at January 1, 2019	47,642,672	\$	60,872	\$	2,198	\$	4,321	\$	(562)	\$	33,867	\$	100,696
Shares issued on exercise of stock options	52,782		113		(38)		-		-		-		75
Share-based compensation (note 16)	278,332		908		1,413		-		-		-		2,321
Shares issued on exercise of warrants	300,000		614		(148)		-		-		-		466
Shares issued pursuant to public offering of common shares, net of issuance costs (note 16)	1,000,000		13,928		-		-		-		-		13,928
Cumulative translation adjustment	-		-		-		-		80		-		80
Reclassification of previously recorded revaluation gain of land (note 6)	-		-		-		(970)		-		-		(970)
Net income	-		-		-		-		-		17,536		17,536
Balance at June 30, 2019	49,273,786	\$	76,435	\$	3,425	\$	3,351	\$	(482)	\$	51,403	\$	134,132

 $The\ accompanying\ notes\ are\ an\ integral\ part\ of\ these\ condensed\ consolidated\ interim\ financial\ statements.$

Condensed Consolidated Interim Statements of Income (Loss) and Comprehensive Loss (In thousands of United States dollars, except per share data) (Unaudited)

	Three Months Ended June 30,				S	Six Months Ended June 30,				
	2019			2018	2019			2018		
Sales (note 14)	\$ 41,329 (44,263)		\$	\$ 42,039 (41,150)		\$ 73,219 (75,845)		71,529 (67,053)		
Cost of sales (note 11) Change in biological asset (note 5)		630		856		530		197		
Selling, general and administrative expenses (note 11)		(4,830)		(3,826)		(10,265)		(7,301)		
Loss from operations		(7,134)		(2,081)		(12,361)		(2,628)		
Interest expense, net		(503)		(691)		(1,110)		(1,289)		
Foreign exchange gain (loss)		243		(21)		521		(14)		
Other income, net		282		26		150		44		
Share of income (loss) from joint ventures (note 7)		13,841		(104)		18,110		(341)		
Gain on disposal of assets (note 7)						13,566				
Income (loss) before income taxes		6,729		(2,871)		18,876		(4,228)		
Recovery of (provision for) income taxes		3,160		589		(1,340)		802		
Net income (loss)	\$	9,889	\$	(2,282)	\$	17,536	\$	(3,426)		
Basic income (loss) per share (note 15)	\$	0.20	\$	(0.05)	\$	0.36	\$	(0.08)		
Diluted income (loss) per share (note 15)	\$	0.20	\$	(0.05)	\$	0.35	\$	(0.08)		
Other comprehensive income (loss): Foreign currency translation adjustment		36		(34)		80		(89)		
Comprehensive income (loss)	\$	9,925	\$	(2,316)	\$	17,616	\$	(3,515)		

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

Condensed Consolidated Interim Statements of Cash Flows

(In thousands of United States dollars)

(Unaudited)

	S	Six Months E	nded Jui	l June 30,	
	2019			2018	
Cash flows used in operating activities:					
Net income (loss)	\$	17,536	\$	(3,426)	
Adjustments to reconcile net income (loss) to net cash					
used in operating activities:					
Depreciation and amortization		3,766		3,523	
Share of (income) loss from joint ventures (note 7)		(18,110)		341	
Interest expense		1,457		1,289	
Interest income		(347)		-	
Gain on disposal of assets (note 7)		(13,566)		-	
Share-based compensation (note 16)		2,321		256	
Deferred income taxes		338		(819)	
Change in biological asset (note 5)		(530)		(197)	
Changes in non-cash working capital items (note 13)		(527)		(6,458)	
Net cash used in operating activities		(7,662)		(5,491)	
Cash flows used in investing activities:					
Purchases of property, plant and equipment, net of rebate		(1,096)		(1,440)	
Note receivables to joint ventures (note 7)		(5,475)		-	
Proceeds from sale of asset		60		_	
Investment in joint ventures (note 7)		(316)		_	
Net cash used in investing activities		(6,827)		(1,440)	
Cash flows from financing activities:					
Proceeds from borrowings		3,000		7,000	
Repayments on borrowings		(1,709)		(917)	
Interest paid on long-term debt, net		(1,063)		(1,289)	
Proceeds from issuance of common stock pursuant to public offering, net		13,930		7,755	
Proceeds from exercise of stock options		74		263	
Payments on capital lease obligations		(423)		(34)	
Proceeds from exercise of warrants		466		-	
Net cash provided by financing activities		14,275		12,778	
Effect of exchange rate changes on cash and cash equivalents				(5)	
Net decrease in cash and cash equivalents		(214)		5,842	
Cash and cash equivalents, beginning of period		11,920		7,091	
Cash and cash equivalents, end of period	\$	11,706	\$	12,933	
Cumlomental and flowinformation.					
Supplemental cash flow information:	¢		¢		
Income taxes paid	\$		\$	-	

Notes to Condensed Consolidated Interim Financial Statements for the Three and Six Months Ended June 30, 2019 and 2018

(In thousands of United States dollars, except share and per share amounts, unless otherwise noted)

1 NATURE OF OPERATIONS

Village Farms International, Inc. ("VFF" the parent company, together with its subsidiaries, the "Company") is incorporated under the *Canada Business Corporation Act*. VFF's principal operating subsidiaries as at June 30, 2019 are Village Farms Canada Limited Partnership ("VFCLP"), Village Farms, L.P. ("VFLP"), and VF Clean Energy, Inc. ("VFCE"). The address of the registered office of VFF is 4700 80th Street, Delta, British Columbia, Canada, V4K 3N3. VFF owns a 65% equity interest in Village Fields Hemp USA LLC ("VF Hemp"), a 60% equity interest in Arkansas Valley Green and Gold Hemp ("AVGG Hemp) and a 50% equity interest in Pure Sunfarms Corp. ("Pure Sunfarms"), all of which are recorded as Investments in Joint Ventures (note 7).

The Company's shares are listed on the Toronto Stock Exchange under the symbol VFF and are also listed in the United States on the Nasdaq Capital Market ("Nasdaq") under the symbol VFF.

The Company owns and operates sophisticated, highly intensive agricultural greenhouse facilities in British Columbia and Texas, where it produces, markets and sells premium-quality tomatoes, bell peppers, and cucumbers. The Company also markets and sells third party produce through its subsidiaries. The Company, through its subsidiary VFCE, owns and operates a 7.0 MW power plant that generates electricity. The Company's joint venture, Pure Sunfarms, is a licensed producer and supplier of cannabis products to be sold to other licensed providers and provincial governments across Canada and internationally. The Company's joint ventures, VF Hemp and AVGG Hemp, are cultivators and extractors of high cannabidiol ("CBD") hemp in multiple states throughout the United States.

2 BASIS OF PRESENTATION

Statement of Compliance

The Company's unaudited condensed consolidated interim financial statements ("interim financial statements") have been prepared in accordance with International Financial Reporting Standards ("IFRS") and its interpretations, as issued by the International Accounting Standards Board ("IASB"), as applicable to interim financial statements, including International Accounting Standard ("IAS") 34, Interim Financial Reporting. They do not include all of the information required for full annual financial statement disclosures and should be read in conjunction with the Company's audited annual consolidated financial statements for the year ended December 31, 2018, which were prepared in accordance with IFRS.

Basis of Presentation

The interim financial statements are prepared on a going concern basis. The accounting policies have been applied consistently in all material respects. These interim financial statements have been prepared by applying the same accounting policies, assessments of estimates and judgments, and methods of computation as compared with the most recent annual consolidated financial statements with the exception of IFRS 16, *Leases* as described in Note 3.

Basis of Measurement

The interim financial statements have been prepared on the historical cost basis except for the following material items in the interim statement of financial position ("interim statement of financial position"):

- biological assets are measured at fair value less costs to sell;
- land is valued at fair market value; and
- marketable equity securities are measured at fair value through profit and loss.

Functional and Presentation Currency

The functional currency for each entity included in these interim financial statements is the currency of the primary economic environment in which the entity operates. These interim financial statements are presented in United States dollars ("U.S. dollars") which have been rounded to the nearest thousands, except per share amounts. Currency conversion to U.S. dollars is performed in accordance with IAS 21, *The Effects of Changes in Foreign Exchange Rates*.

Notes to Condensed Consolidated Interim Financial Statements for the Three and Six Months Ended June 30, 2019 and 2018

(In thousands of United States dollars, except share and per share amounts, unless otherwise noted)

3 CHANGES IN ACCOUNTING POLICIES

These changes were made in accordance with the applicable transitional provisions.

Amendments to IFRS 11, *Joint Arrangements*, and IAS 28, *Investments in Associates and Joint Ventures* establishes the criteria for accounting for joint ventures. Investments in joint ventures are accounted for using the equity method. The equity method involves recording the initial investment at cost and subsequently adjusting the carrying value of the investment for the proportionate share of the profit or loss, other comprehensive income or loss and any other changes in the joint venture's net assets such as dividends. At each statement of financial position date, the Company will consider whether there is objective evidence that its investment in the joint venture is impaired. If there is such evidence of impairment, the Company will determine the amount of the impairment and a loss will be recorded in the condensed consolidated interim statement of income (loss) ("interim statement of income (loss)"). The adoption of the amendments to IFRS 11 did not have and impact on the Company's interim financial statements.

IFRS 16, *Leases*, was issued in January 2016 to replace IAS 17, *Leases*, and related Interpretations. IFRS 16 establishes the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract, i.e. the customer (lessee) and the supplier (lessor) to increase transparency and comparability among organizations by requiring the recognition of right-of-use assets and lease liabilities on the balance sheet.

On January 1, 2019, the Company adopted IFRS 16 using the updated modified retrospective transition approach and did not restate prior periods. The Company's classes of assets include land leases, building leases and equipment leases.

On adoption, the Company recognized lease liabilities in relation to leases which had previously been classified as 'operating leases' under the principles of IAS 17, *Leases*. These lease liabilities were measured at the present value of the remaining lease payments, discounted using the borrowing rate of the Company. The weighted average incremental borrowing rate applied to the lease liabilities on January 1, 2019 was 6.25%. These leases are included in right-of-use assets, short-term lease liabilities and long-term lease liabilities in our consolidated balance sheet. Right-of-use assets are amortized on a straight-line basis over the lease term.

For leases previously classified as finance leases the entity recognized the carrying amount of the lease asset and lease liability immediately before transition as the carrying amount of the right of use asset and the lease liability at the date of initial application.

Additionally, the Company has elected the short-term lease exception for all classes of assets, and does not apply the recognition requirements for leases of 12 months or less, and recognizes lease payments for short-term leases as expense either straight-line over the lease term or as incurred depending on whether the lease payments are fixed or variable. These elections are applied consistently for all leases.

	2019
Operating lease commitments disclosed as at December 31, 2018	\$ 5,064
Less: short-term leases recognized on a straight-line basis as expense	(210)
	4,854
Discounted using the lessee's incremental borrowing rate of 6.25% at the date of initial	4,269
Add: additional leases identified on adoption of IFRS 16	88
Add: finance lease liabilities recognized as at December 31, 2018	 180
Lease liability recognized as at January 1, 2019	\$ 4,537
Of which are:	
Current lease liabilities	1,022
Non-current lease liabilities	3,515
	\$ 4,537

Notes to Condensed Consolidated Interim Financial Statements for the Three and Six Months Ended June 30, 2019 and 2018

(In thousands of United States dollars, except share and per share amounts, unless otherwise noted)

The recognized right-of-use assets relate to the following types of assets:

		December 31, 2018	Janu	ary 1, 2019
Land	\$	-	\$	140
Building		-		4,017
Equipment	-	176		380
Total right-of-use assets	\$	176	\$	4,537

4 INVENTORIES

	June 30, 2019		December 31, 2018	
Deferred crop costs	\$	20,759	\$	24,649
Purchased produce inventory		457		643
Biological asset adjustment (note 5)		(3,541)		(2,871)
Spare parts inventory		69		64
	\$	17,744	\$	22,485

The cost of inventories recognized as expense and included in cost of sales for the three months ended June 30, 2019 amounted to \$37,143 (2018 - \$34,375) and \$62,881 for the six months ended June 30, 2019 (2018 - \$54,580). The biological asset adjustment reclassifies actual costs incurred for the biological asset from inventories to biological asset on the interim statements of financial position.

5 BIOLOGICAL ASSET

Information about the biological asset presented on the interim statements of financial position and in the interim statements of income (loss) is as follows:

	June 30, 2019		ember 31, 2018	June	30, 2018
Estimated sales value - biological asset	\$	10,825	\$ 8,004	\$	12,803
Less Estimated remaining costs to complete		4,793	3,304		5,114
Estimated selling costs		603	 470		769
Fair value of biological asset less costs to sell Less actual costs		5,429 3,540	 4,230 2,871		6,920 4,530
Increase in fair value of biological asset over cost Fair value over cost of harvested and sold		1,889	1,359		2,390
biological asset - beginning of year		1,359	 2,193		2,193
Change in biological asset	\$	530	\$ (834)	\$	197

6 PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment consist of the following:

		Leasehold						
		and land		Ma	achinery			
		improve-			<u>and</u>	Cons	truction	
	Land	ments	Buildings	Eq	uipment	in p	rocess	<u>Total</u>
At January 1, 2019								
Cost	\$ 9,047	\$ 3,820	\$ 77,003	\$	65,664	\$	552	\$ 156,086
Accumulated depreciation		(2,308)	(36,289)		(40,186)			(78,783)
Net book value (note 3)	\$ 9,047	\$ 1,512	\$ 40,714	\$	25,478	\$	552	\$ 77,303

Notes to Condensed Consolidated Interim Financial Statements for the Three and Six Months Ended June 30, 2019 and 2018

(In thousands of United States dollars, except share and per share amounts, unless otherwise noted)

Six Months ended June 30, 2019						
Opening net book value	\$ 9,047	\$ 1,512	\$ 40,714	\$ 25,478	\$ 552	\$ 77,303
Additions/transfers	-	-	-	608	616	1,224
Placed in service	-	-	-	-	(430)	(430)
Disposals	(1,848)	-	(4,552)	(4,178)	-	(10,578)
Accum deprec on disposal	-	-	1,934	2,305	-	4,239
Depreciation expense	-	(43)	(1,153)	(2,031)	-	(3,227)
Foreign currency translation						
adjustment			11_	 123		134
Closing net book value	\$ 7,199	\$ 1,469	\$ 36,954	\$ 22,305	\$ 738	\$ 68,665
At June 30, 2019						
Cost	\$ 7,199	\$ 3,820	\$ 72,456	\$ 61,573	\$ 738	\$ 145,786
Accumulated depreciation	-	(2,351)	(35,502)	(39,268)	-	(77,121)
Net book value	\$ 7,199	\$ 1,469	\$ 36,954	\$ 22,305	\$ 738	\$ 68,665

Depreciation related to the greenhouse facilities and equipment is expensed in cost of sales. Land is the only item of property, plant and equipment that is stated at fair values. On March 31, 2019, Pure Sunfarms exercised its option to acquire the Delta 2 assets and operations. Delta 2 land was disposed of as part of that transaction (note 7). The revaluation surplus related to Delta 2 of \$1.0 million, net of taxes, that was previously recorded as a component of equity, was reclassified and included as part of the gain on disposal of assets recorded in the interim statements of income (loss).

7 INVESTMENT IN JOINT VENTURES

Pure Sunfarms Corp.

On June 6, 2017, the Company entered into an agreement to form Pure Sunfarms, a B.C. corporation, with Emerald Health Therapeutics Inc. ("Emerald"). The purpose of Pure Sunfarms is to produce, market and distribute cannabis in Canada. Village Farms has a 50% ownership interest in Pure Sunfarms in the form of common shares. The Company has concluded that the agreement constitutes a joint arrangement where joint control is shared with Emerald and therefore has accounted for Pure Sunfarms in accordance with IFRS 11 and IAS 28, using the equity method.

On July 5, 2018, the Company and Emerald Health Therapeutics Canada Inc. (a subsidiary of Emerald) (together, the "Shareholders") entered into a Shareholder Loan Agreement (the "Loan Agreement") with Pure Sunfarms, whereby, as at June 30, 2019, the Shareholders had each contributed \$10,082 (CA\$13,000) in the form of a demand loan to Pure Sunfarms. Effective January 1, 2019, the loan amounts bear simple interest at the rate of 6.2% per annum, calculated semi-annually. Interest will accrue and be payable upon demand being made by both Shareholders (see note 10).

On March 31, 2019, Pure Sunfarms exercised its option to utilize the Delta 2 assets and operations. The contribution of the assets has been accounted for as a disposal of the land, greenhouse facility and other assets in exchange for 25,000,000 common shares of Pure Sunfarms. This was a non-cash transaction, and it was estimated that the fair value of the land, building and other assets was \$18.7 million (CA\$25 million) at the date of contribution. The Company recognized a gain of \$13.6 million on the contribution of the fixed assets. The Company had previously recorded a fair value increase on the Delta 2 land being contributed (2016 - \$2.0 million), which was recorded in accumulated other comprehensive income, net of taxes of \$1.0 million. As a result of the contribution of the Delta 2 land, this amount has been recycled to the interim statements of income, and has been included in the gain noted above. As at June 30, 2019, the total investment in Pure Sunfarms of US\$55.1 million is recorded in the interim statements of financial position. Final determination with respect to the transfer of the land, building and equipment will not be made until year end. As such, the investment and related gain on disposal of assets may be adjusted at year end.

VILLAGE FARMS INTERNATIONAL, INC.Notes to Condensed Consolidated Interim Financial Statements for the Three and Six Months Ended June 30, 2019 and 2018

(In thousands of United States dollars, except share and per share amounts, unless otherwise noted)

The Company's share of the joint venture consists of the following:

Balance, January 1, 2019	\$ 18,108
Investments in joint venture	18,661
Transaction costs	55
Share of net income for the period	18,260
Balance, June 30, 2019	\$ 55,084

Summarized financial information of Pure Sunfarms (in \$000's of CAD):

	June 30, 2019		December 31, 2018	
Current assets				
Cash and cash equivalents (including restricted cash)	\$	18,648	\$	2,362
Trade receivables		15,458		1,312
Inventory		12,632		8,356
FV of biological asset in inventory		19,894		-
Biological asset		16,546		7,388
Other current assets		588		996
Non-current assets		108,611		67,263
Current liabilities				,
Trade payables		(2,593)		(9,361)
Borrowings due to joint venture partners		(27,333)		(26,523)
Other current liabilities		(12,783)		(3,582)
Non-current liabilities				-
Borrowings – long term		(18,000)		-
Deferred tax liability		(4,320)		(2,688)
Net assets	\$	127,348	\$	45,523
Summarized financial information of Pure Sunfarms (in \$000'	s of CAD):			
-	Jun	ne 30, 2019	Decen	nber 31, 2018
The state of the s				

Sι

	June	30, 2019	December 51, 2018		
Reconciliation of net assets:					
Accumulated retained earnings	\$	54,158	\$	5,523	
Contributions from joint venture partners		73,190		40,000	
Net assets	\$	127,348	\$	45,523	

Notes to Condensed Consolidated Interim Financial Statements for the Three and Six Months Ended June 30, 2019 and 2018

(In thousands of United States dollars, except share and per share amounts, unless otherwise noted)

Summarized financial information of Pure Sunfarms (in \$000's of CAD):

	Three months ended					Six months ended			
		June	30,		June 30,				
	2019		2018		3 2019		9 2		
Revenue	\$	32,356	\$	-	\$	46,715	\$	-	
Cost of sales*		(5,293)		-		(10,369)		-	
Selling, general and administrative expenses		(2,384)		(761)		(3,712)		(1,315)	
Realized FV included in inventory sold		(19,148)				(27,424)			
Change in fair value of bio-asset		38,688		422		55,078		422	
Income (loss) from operations		44,219		(339)		60,288		(893)	
Interest expense		389		-		390		-	
Foreign exchange loss (gain)		33		(78)		(19)		(28)	
Other income, net		(4)		-		(17)		-	
Income (loss) before taxes		43,801		(261)		59,934		(865)	
Provision for recovery of income taxes		(6,594)		-		(11,299)		-	
Net income (loss)	\$	37,207	\$	(261)	\$	48,635	\$	(865)	

^{*}Included in cost of sales is CA\$1,123 of amortization expense.

Village Fields Hemp USA LLC

On February 27, 2019, the Company entered into a joint venture with Nature Crisp, LLC ("Nature Crisp") to form VF Hemp for the objective of outdoor cultivation of high percentage cannabidiol ("CBD") hemp and CBD extraction in multiple states throughout the United States. VF Hemp is 65% owned by the Company and 35% owned by Nature Crisp. Under the terms of the VF Hemp Joint Venture Agreement, the Company will lend approximately US\$15 million to VF Hemp for start-up costs and working capital. Capital investment for extraction capabilities is to be determined and dependent on future decisions with respect to the locations of hemp production and the extraction operations. The Company has concluded that the agreement constitutes a joint arrangement where joint control is shared with Nature Crisp and therefore has accounted for VF Hemp in accordance with IFRS 11 and IAS 28, using the equity method.

On March 25, 2019, the Company entered into a Grid Loan Agreement (the "Grid Loan") with VF Hemp, whereby, as at June 30, 2019, the Company had advanced \$5,193 in the form of a grid loan to VF Hemp. The Grid Loan has a maturity date of March 25, 2022, and will bear simple interest at the rate of 8% per annum, calculated monthly (note 10).

The Company's share of the joint venture consists of the following:

Balance, beginning of the period	\$	-
Investments in joint venture		7
Share of net loss		(133)
Transaction costs		219
Balance, June 30, 2019	\$	93
	· · · · · · · · · · · · · · · · · · ·	

Notes to Condensed Consolidated Interim Financial Statements for the Three and Six Months Ended June 30, 2019 and 2018

(In thousands of United States dollars, except share and per share amounts, unless otherwise noted)

Summarized financial information of VF Hemp:

Current assets	
Cash and cash equivalents	\$ 73
Inventory	2,486
Prepaid expenses	1,439
Non-current assets	2,805
Current liabilities	(1,805)
Non-current liabilities	 (5,193)
Net assets	\$ (195)
Reconciliation of net assets:	
Net loss for the six months ended June 30, 2019	\$ (205)
Contributions from joint venture partners	 10
Net assets	\$ (195)

Arkansas Valley Green and Gold Hemp

Balance, beginning of the period

On May 21, 2019, the Company entered into a joint venture with Arkansas Valley Hemp, LLC ("AV Hemp") for the objective of outdoor cultivation of high percentage cannabidiol (CBD) hemp and CBD extraction in Colorado. The joint venture, AVGG Hemp, is 60% owned by the Company, 35% owned by AV Hemp, and 5% owned by VF Hemp.

Under the terms of the AVGG Hemp Joint Venture Agreement, the Company will lend approximately US\$5 million to AVGG Hemp for start-up costs and working capital. The loans bear simple interest at the rate of 8% per annum, calculated monthly (note 10). To the extent cash is available from positive cash flow, the AVGG Hemp has agreed to repay the Company with respect to any such loans, in the range of \$2 million to \$5 million in the initial two years following the formation of AVGG Hemp. As at June 30, 2019, the Company had loaned AVGG Hemp approximately \$552.

The Company has concluded that the agreement constitutes a joint arrangement where joint control is shared with AV Hemp and therefore has accounted for AVGG Hemp in accordance with IFRS 11 and IAS 28, using the equity method.

The Company's share of the joint venture consists of the following:

Investments in joint venture	·	6
Share of net loss		(17)
Transaction costs		31
Balance, June 30, 2019	\$	20
Summarized financial information of AVGG Hemp: Current assets		
Cash and cash equivalents	\$	10
Inventory	*	533
Other current assests		9
Current liabilities		(17)
Non-current liabilities		(552)
Net assets	\$	(17)

Notes to Condensed Consolidated Interim Financial Statements for the Three and Six Months Ended June 30, 2019 and 2018

(In thousands of United States dollars, except share and per share amounts, unless otherwise noted)

Reconciliation of net assets:

Net loss for the six months ended June 30, 2019	\$ (27)
Contributions from joint venture partners	10
Net assets	\$ (17)

Summarized joint ventures' information:

	joint v	stment in ventures at 30, 2019
Pure Sunfarms	\$	55,084
VF Hemp		93
AVGG Hemp		20
Total	\$	55,197

Share of income (loss) from joint ventures

				,	,				
	T	Three months ended June 30,			,	Six months ended June 30,			
		2019		2018		2019	,	2018	
Pure Sunfarms	\$	13,961	\$	(104)	\$	18,260	\$	(341)	
VF Hemp		(104)		-		(133)		-	
AVGG Hemp		(16)		-		(17)		-	
Total	\$	13,841	\$	(104)	\$	18,110	\$	(341)	

8 DEBT

	<u>June 30, 2019</u>		<u>December 31, 2018</u>	
Long-term debt:				
Opening balance	\$	35,859	\$	38,380
IFRS 9 adjustment for deferred financing		-		260
Repayment of debt		(1,709)		(2,738)
Foreign currency translation		80		(43)
Closing balance	\$	34,230	\$	35,859
Current portion	\$	3,439	\$	3,414
Non-current portion		30,791		32,445
	\$	34,230	\$	35,859

The Company's subsidiary has two loan agreements in place with a Canadian Chartered bank. As at June 30, 2019, the balance on the non-revolving fixed rate loan was US\$1,219 (December 31, 2018 – US\$1,279) and the balance on the uncommitted credit facility for capital expenditures was US\$127 (December 31, 2018 – US\$138).

The Company has a line of credit agreement with a Canadian Chartered Bank ("Operating Loan"). The revolving Operating Loan has a line of credit up to CA\$13,000 and variable interest rates with a maturity date on May 31, 2021 and is subject to margin requirements stipulated by the bank. As at June 30, 2019, US\$5,000 was drawn on this facility (December 31, 2018 - US\$2,000), which is available to a maximum of CA\$13,000, less outstanding letters of credit totaling US\$150 and CA\$38.

The Company's borrowings ("Credit Facilities") are subject to certain positive and negative covenants. As at June 30, 2019 the Company was in compliance with all covenants on its Credit Facilities.

Accrued interest payable on the credit facilities and loans as at June 30, 2019 was \$177 (December 31, 2018 - \$184) and these amounts are included in accrued liabilities in the interim statement of financial position.

As security for the FCC Loan, the Company has provided promissory notes, a first mortgage on the VFF-owned greenhouse properties (excluding the Delta 3 and Delta 2 greenhouse facilities), and general security agreements over its assets. In addition,

Notes to Condensed Consolidated Interim Financial Statements for the Three and Six Months Ended June 30, 2019 and 2018

(In thousands of United States dollars, except share and per share amounts, unless otherwise noted)

the Company has provided full recourse guarantees and has granted security therein. The carrying value of the assets and securities pledged as collateral as at June 30, 2019 was \$158,887 (December 31, 2018 – \$114,554).

As security for the Operating Loan, the Company has provided promissory notes and a first priority security interest over its accounts receivable and inventory. In addition, the Company has granted full recourse guarantees and security therein. The carrying value of the assets pledged as collateral as at June 30, 2019 was \$36,996 (December 31, 2018 - \$38,007).

The aggregate annual principal maturities of long-term debt for the next five years and thereafter are as follows:

Remainder of 2019	\$ 1,718
2020	3,426
2021	28,567
2022	344
2023	175
Thereafter	-
	\$ 34,230

9 FINANCIAL INSTRUMENTS

As at June 30, 2019 and December 31, 2018, the Company's financial instruments included cash and cash equivalents, trade receivables, notes receivable, other receivables, patronage stock, accounts payable, other current liabilities and notes payable. Due to the short-term maturities of cash and cash equivalents, accounts receivable, accounts payable and other current liabilities, the carrying amounts approximate fair value at the respective statement of financial position dates. The carrying value of the notes receivable and notes payable approximate their fair value based on a comparison with the prevailing market interest rates. The fair values of the Company's notes receivable and notes payable are level 2 measurements in the fair value hierarchy. All other financial assets and liabilities are level 1.

There were no financial instruments categorized as Level 3 as at June 30, 2019 and December 31, 2018. There were no transfers of assets or liabilities between levels during the three and six months ended June 30, 2019 and December 31, 2018, respectively.

Interest income, interest expense and gains and losses from loans, receivables and other financial liabilities are recognized in the interim statements of income (loss). The following table summarizes interest income and expense for the three and six months ended June 30:

	Three months ended June 30,				Six	Six months ended June 30,			
	2019		2	2018	2019		2018		
Interest income earned on cash and cash equivalents	\$	-	\$	3	\$	25	\$	3	
Interest income earned on other financial assets	\$	211	\$	-	\$	322	\$	-	
Interest expense from other financial liabilities	\$	714	\$	688	\$	1,457	\$	1,286	

Management of financial risks

The Company, through its financial assets and liabilities, is exposed to various risks. The following provides a measurement of some of these risks as at June 30, 2019 and December 31, 2018. The Company uses financial instruments only for risk management purposes, not for generating trading profit.

i) Credit risk

Credit risk is the risk that the Company will incur a loss due to the failure by its customers or other parties to meet their contractual obligations. Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents, trade receivables and other receivables. The Company limits its exposure to credit risk by placing its cash and cash equivalents with high credit quality financial institutions.

The Company's trade receivables had two customers that represented more than 10% of the balance of trade receivables, representing 11.7% and 11.0% of the balance of trade receivables as at June 30, 2019 (December 31, 2018 - two customer represented 13.8% and 11.5%). The Company believes that its expected credit losses are limited due to the protection afforded

Notes to Condensed Consolidated Interim Financial Statements for the Three and Six Months Ended June 30, 2019 and 2018

(In thousands of United States dollars, except share and per share amounts, unless otherwise noted)

to the Company by the *Perishable Agricultural Commodities Act* (the "PACA") for its sales in the United States, which represent the majority of the Company's annual sales. The PACA protection gives a claim filed under the PACA first lien on all PACA assets (which include cash and trade receivables of the debtor).

As at June 30, 2019, the allowance for doubtful accounts balance was calculated based on the expected credit loss model and expected credit losses continues to be insignificant.

As at June 30, 2019, 97.7% (December 31, 2018 - 90.3%) of trade receivables were outstanding less than 30 days, 1.1% (December 31, 2018 - 8.3%) were outstanding for between 30 and 90 days and the remaining 1.2% (December 31, 2018 - 1.4%) were outstanding for more than 90 days. Trade receivables are considered past due based on the contract terms agreed to with a customer. Aged receivables that are past due are not considered impaired unless customer specific information indicates otherwise.

ii) Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company is exposed to interest rate risk on its long-term debt, for which the interest rates charged fluctuate based on the 90-day LIBOR rate. If interest rates had been 50 basis points higher, the net income during the six months ended June 30, 2019 would have been lower by \$84. This represents \$84 in increased interest expense (2018 - \$95).

iii) Foreign exchange risk

As at June 30, 2019, the Canadian/U.S. foreign exchange rate was CA\$1.00 = US\$0.7636 (December 31, 2018 – US\$0.7336). Assuming that all other variables remain constant, an increase of \$0.10 in the Canadian dollar would have the following impact on the ending balances of certain interim statements of financial position items at June 30, 2019 and December 31, 2018 with the net foreign exchange gain or loss directly impacting net income (loss).

	June	30, 2019	December 31, 2018	
Financial assets		_		_
Cash and cash equivalents	\$	837	\$	839
Trade receivables		504		328
JV notes receivable		1,366		1,335
Financial liabilities				
Trade payables and accrued liabilities		(693)		(373)
Loan payable		(176)		(193)
Net foreign exchange gain (loss)	\$	1,838	\$	1,936

iv) Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its obligations as they fall due. The following are the contractual maturities of financial liabilities as at June 30, 2019:

Financial liabilities Total		1 year	2-3 years	4-5 years	More than 5 years		
Long-term debt	\$ 36,681	\$ 3,717	\$ 32,623	\$ 341	\$ -		
Line of credit	5,000	5,000	-	-	-		
Trade payables	9,389	9,389	-	-	-		
Accrued liabilities	6,729	6,729	-	-	-		
Lease liabilities	4,739	1,149	2,226	1,243	121		
Other liabilities	1,205		1,205				
Total	\$ 63,743	\$ 25,984	\$ 36,054	\$ 1,584	\$ 121		

It is the Company's intention to meet these obligations through the collection of current accounts receivable and cash from sales. If the current resources and cash generated from operations are insufficient to satisfy its obligations, the Company may seek to issue additional equity or to arrange debt or other financing. In addition, as at June 30, 2019, the Company has an operating credit facility of up to CA\$13,000, of which US\$5,000 was drawn as at June 30, 2019, less outstanding letters of credit totaling US\$150 and CA\$38.

Notes to Condensed Consolidated Interim Financial Statements for the Three and Six Months Ended June 30, 2019 and 2018

(In thousands of United States dollars, except share and per share amounts, unless otherwise noted)

10 RELATED PARTY TRANSACTIONS AND BALANCES

On February 13, 2019, the Company announced that Pure Sunfarms had entered into a credit agreement with Bank of Montreal, as agent and lead lender, and Farm Credit Canada, as lender, in respect of a CA\$20 million secured non-revolver term loan (the "Credit Facility"). The Credit Facility, which matures on February 7, 2022, is secured by the Delta 3 facility, and contains customary financial and restrictive covenants. The Company is not a party to the Credit Facility but has provided a limited guarantee in the amount of CA\$10 million in connection with the Credit Facility.

As at June 30, 2019, the Company had amounts due from its joint venture, Pure Sunfarms, totaling \$168 (December 31, 2018 - \$1,079) primarily for consulting services and the reimbursement of expenses which occurred in the year. These amounts are non-interest bearing and due on demand. On July 5, 2018, the Shareholders entered into a Loan Agreement with Pure Sunfarms, whereby, as at June 30, 2019, the Shareholders had each contributed CA\$13,000 (US\$10,434) in the form of a demand loan to Pure Sunfarms. Effective January 1, 2019, the loan amounts bear simple interest at the rate of 6.2% per annum, calculated semi-annually. Interest is accrued and payable on demand being made by either Shareholder. Prior to January 1, 2019, the loan amount bore interest at the rate of 8.0%. These amounts are included in amounts due from joint venture in the interim statements of financial position.

On March 25, 2019, the Company entered into a Grid Loan Agreement (the "Grid Loan") with VF Hemp, whereby, as at June 30, 2019, the Company had contributed \$5,193 in the form a grid loan to VF Hemp. The Grid Loan has a maturity date of March 25, 2022, and will bear simple interest at the rate of 8% per annum, calculated monthly.

Under the terms of the AVGG Hemp Joint Venture Agreement, the Company will lend approximately US\$5 million to AVGG Hemp for start-up costs and working capital. The loans will bear simple interest at the rate of 8% per annum, calculated monthly (note 7). As at June 30, 2019, the Company had loaned AVGG Hemp approximately \$552 (note 7).

One of the Company's employees is related to a member of the Company's executive management team and received approximately \$54 in salary and benefits during the six months ended June 30, 2019 (2018 - \$54).

Included in other assets as at December 31, 2018 is a \$64 promissory note that represents the unpaid amount the Company advanced to an employee in connection with a relocation at the request of the Company. The promissory note was paid in full June 10, 2019.

11 EXPENSES BY NATURE

The following table outlines the Company's significant expenses by nature:

Cost of sales	Th	ree months	ended J	une 30,	Six months ended June 30,			
	2019		2	2018		2019		2018
Purchased produce	\$	13,026	\$	11,581	\$	24,701	\$	19,767
Raw materials and consumables used		14,444		12,829		20,078		16,265
Depreciation and amortization		1,814		1,694		3,712		3,465
Transportation and storage		6,232		5,905		10,989		10,441
Employee compensation and benefits		8,747		9,141		16,365		17,115
	\$	44,263	\$	41,150	\$	75,845	\$	67,053
Selling, general and administrative expenses	Three months e		ths ended June 30,		Six months		ended June 30,	
		2019	2018		2019		2018	
Employee benefits - salaries and short-term								
benefits	\$	2,989	\$	2,294	\$	6,494	\$	4,464
Marketing		52		92		53		178
Professional services		926		659		1,986		1,070
Office expenses		422		449		866		891
T		722		777		000		0,1
Other		441		332		866		698 7,301

Notes to Condensed Consolidated Interim Financial Statements for the Three and Six Months Ended June 30, 2019 and 2018

(In thousands of United States dollars, except share and per share amounts, unless otherwise noted)

Employee compensation and benefits	Three months ended June 30,					Six months ended June 3			
	2019			2018		2019		2018	
Salaries and short-term employee benefits	\$	10,824	-	\$	11,297	\$	20,538	\$	21,323
Share-based compensation		912	_		138		2,321		256
	\$	11,736	_	\$	11,435	\$	22,859	\$	21,579

12 DEFERRED INCOME TAX

Income tax expense is recognized based on management's best estimate of the weighted average annual income tax rate expected for the full financial year. The estimated average annual rate used for the six months ended June 30, 2019 was 24%, excluding the change in biological asset as reported on the interim statements of income (loss), and 25% for the six months ended June 30, 2018.

13 CHANGES IN NON-CASH WORKING CAPITAL ITEMS

	Six months ended June 30,					
	- /	2019	2	018		
Trade receivables	\$	(2,524)	\$	(3,219)		
Inventories		3,405		(2,870)		
Inventories reclassified to biological asset		670		(921)		
Prepaid expenses and deposits		(1,219)		109		
Trade payables		(5,189)		(2,150)		
Accrued liabilities and taxes		3,145		3,081		
Other assets/other liabilities, net		1,185		(488)		
	\$	(527)	\$	(6,458)		

14 SEGMENT AND GEOGRAPHIC INFORMATION

The Company's two reporting segments include the Produce business and the Energy business. The Produce business produces, markets, and sells the product group which consists of premium quality tomatoes, bell peppers and cucumbers. The Energy business produces power that it sells per a long-term contract to its one customer. The Company's Chief Operating Decision Makers also review the results of the Company's three joint ventures on a quarterly basis (note 7).

The Company's primary operations are in the United States and Canada. Net sales by the countries in which its customers are located are as follows:

	Th	Three months ended June 30,				Six months ended June 30,				
		2019 2018		2018	2019		2018			
Net Sales				_		_				
United States	\$	33,661	\$	32,892	\$	61,860	\$	60,318		
Canada		7,423		8,693		10,802		10,232		
Energy - Canada		245		454		557		979		
	\$	41,329	\$	42,039	\$	73,219	\$	71,529		

The Company's property, plant and equipment, net of accumulated depreciation, and right-of-use assets are located as follows:

	June	30, 2019	Decem	per 31, 2018	
United States	\$	43,617	\$	43,651	
Canada		25,902		30,459	
Energy - Canada		3,134		3,369	
	\$	72,653	\$	77,479	

Notes to Condensed Consolidated Interim Financial Statements for the Three and Six Months Ended June 30, 2019 and 2018

(In thousands of United States dollars, except share and per share amounts, unless otherwise noted)

Depreciation and amortization charges in the Produce business for the three and six months ended June 30, 2019 were \$1,882 (2018 - \$1,534) and \$3,312 (2018 - \$3,112), respectively. Depreciation and amortization charges in the Energy business for the three and six months ended June 30, 2018 were \$226 (2018 - \$188) and \$454 (2018 - \$411), respectively.

15 INCOME PER SHARE

Basic income per share is calculated by dividing the net income attributable to owners of the Company by the weighted average number of common shares in issue during the year excluding common shares purchased by the Company and held as treasury shares.

	<u>Th</u> ı	ree months	ended.	<u>June 30, </u>	Six months ended June 30,				
	2019		2019 2018		2019			2018	
Net income (loss) attributable to owners of the Company	\$	9,889	\$	(2,282)	\$	17,536	\$	(3,426)	
Weighted average number of common shares outstanding									
(thousands)		48,825		43,336		48,322		42,894	
Basic income (loss) income per share	\$	0.20	\$	(0.05)	\$	0.36	\$	(0.08)	

Diluted income per share is calculated by adjusting the weighted average number of common shares outstanding to assume conversion of all dilutive potential common shares. The Company's share options are potentially dilutive to common shares. A calculation is done to determine the number of shares that could have been acquired at fair value (determined as the average market share price of the Company's shares for the year) based on the monetary value of the subscription rights attached to outstanding share options. The number of shares calculated above is compared with the number of shares that would have been issued assuming the exercise of the share options. If dilutive effect is less than zero, then issuance is anti-dilutive and is excluded from dilutive income per share calculation.

	Three months	ended June 30,	Six months ended June 30,			
	2019	2018	2019	2018		
Net income (loss) attributable to owners of the Company	\$ 9,889	\$ (2,282)	\$ 17,536	\$ (3,426)		
Weighted average number of common shares outstanding						
(thousands)	48,825	43,336	48,322	42,894		
Adjustment for:						
Share options (thousands)	1,887	<u> </u>	1,837	<u> </u>		
Weighted average number of common shares outstanding						
for diluted earnings per share (thousands)	50,712	43,336	50,159	42,894		
Diluted income (loss) per share	\$ 0.20	\$ (0.05)	\$ 0.35	\$ (0.08)		

For the three and six months ended June 30, 2019, there were options to purchase 2,612,216 (2018 – 2,197,999) and 310,000 (2018 – 2,197,999) shares, respectively, of the Company's common stock that were excluded from the diluted income per share computation because the impact of the assumed exercise of such stock options would have been anti-dilutive during the respective periods.

16 SHAREHOLDERS' EQUITY

In April 2019, the Company completed a bought deal offering of 1,000,000 common shares of the Company at an offering price of CA\$20.00 per offered share for net aggregate proceeds to the Company of approximately CA\$18,700 after deducting offering fees of CA\$1,300.

The Company has a share-based compensation plan. The maximum number of common shares that can be issued upon the exercise of options granted is equal to 10% of the aggregate number of common shares issued and outstanding from time to time. The term during which an option may be exercised is 10 years from the date of the grant. Options generally vest at a rate of 33% per year, beginning one year following the grant date of the options. Share-based compensation expense for the three months and six months ended June 30, 2019 of \$912 (2018 - \$138) and \$2,321 (2018 - \$256), respectively, was recorded in selling, general and administrative expenses and the corresponding amount credited to contributed surplus.

During the six months ended June 30, 2019, 355,000 performance-based restricted share units were granted to Village Farms employees and directors involved with future developments of the Company. Once a performance target is met and the share

Notes to Condensed Consolidated Interim Financial Statements for the Three and Six Months Ended June 30, 2019 and 2018

(In thousands of United States dollars, except share and per share amounts, unless otherwise noted)

units are deemed earned and vested, compensation expense based on the fair value of the share units on the grant date is recorded in selling, general and administrative expenses in the interim statements of income. There were 1,128,333 performance-based restricted share units outstanding as at June 30, 2019, of which 1,034,000 were not vested as at June 30, 2019.

17 REPORTING REQUIREMENTS

Effective January 1, 2020, the Company intends to comply with Securities and Exchange Commission reporting requirements applicable to U.S. domestic issuers. This will also require the Company's financial statements and financial data to be presented under U.S. generally accepted accounting principles ("US GAAP"). Accordingly, the Company will file its annual report on Form 10-K for the year ended December 31, 2019 under US GAAP, and regular periodic reports under both Canadian and U.S. law thereafter under US GAAP.